drugset / Trial / NCT00945178

Double-blind Placebo-controlled 2-part Study Assessing the Safety, Tolerability and PK of AZD1386 in Healthy Volunteers

NCT00945178

Phase 1 Terminated 11 enrolled AstraZeneca
RandomizedParallel-groupTriple-blindBasic science

Summary

The study will investigate how a new formulation of the study drug is absorbed, metabolised and distributed through the body, as well as its safety and tolerability in higher doses when given as single and multiple doses and as a single dose in the presence and absence of naproxen.

Timeline

Start
2009-08
Primary completion
2009-09
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD1386 Small molecule Oral
Subject Naproxen Small molecule 500 mg Oral

Indications

No indication recorded.